Equity Overview
Price & Market Data
Price: $0.002
Daily Change: $0.00 / 0.00%
Daily Range: $0.002 - $0.0048
Market Cap: $13,612,806
Daily Volume: 3,475,785
Performance Metrics
1 Week: 81.82%
1 Month: -33.33%
3 Months: -42.86%
6 Months: 100.0%
1 Year: 100.0%
YTD: -48.72%
Details
Solvonis Therapeutics plc, a clinical-stage biopharmaceutical company, develops novel medicines for addiction and mental health disorders. The company develops SVN-001, an NMDA receptor antagonist that is in Phase III clinical trial for the treatment of severe alcohol use disorder; and SVN-002, which has completed Phase I clinical trial to treat moderate to severe alcohol use disorder. Its pre-clinical stage product candidate includes SVN-SDN-14 for the treatment of post-traumatic stress disorder. The company was formerly known as Graft Polymer (UK) Plc and changed its name to Solvonis Therapeutics plc in January 2025. Solvonis Therapeutics plc was incorporated in 2017 and is headquartered in London, the United Kingdom.